| CAS NO: | 1037543-26-2 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 1037543-26-2 |
| Canonical SMILES | O=C(/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)C)C)OC2=CC=C(C=C2)COC(CCC)=O |
| 分子式 | C31H40O4 |
| 分子量 | 476.7 |
| 溶解度 | DMSO: 5 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ATRA-BA hybrid is a mutual prodrug form of all-transretinoic acid and butyric acid .1ATRA-BA hybrid is cleaved to release ATRA and BA in isolated mouse plasma. It inhibits the growth of MDA-MB-231 breast and PC3 prostate cancer cells with GI50values of 0.01 and 1.02 µM, respectively. ATRA-BA (20 µM) has 15-fold greater antiproliferative activity in PC3 cells compared to an equimolar concentration of ATRA and BA. 1.Gediya, L.K., Khandelwal, A., Patel, J., et al.Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitroJ. Med. Chem.51(13)3895-3904(2008) |
m.cnreagent.com